S&P 500   4,320.06 (-0.23%)
DOW   33,963.84 (-0.31%)
QQQ   357.91 (+0.01%)
AAPL   174.79 (+0.49%)
MSFT   317.01 (-0.79%)
META   299.08 (+1.13%)
GOOGL   130.25 (-0.15%)
AMZN   129.12 (-0.16%)
TSLA   244.88 (-4.23%)
NVDA   416.10 (+1.45%)
NIO   8.54 (+1.07%)
BABA   88.30 (+4.98%)
AMD   96.20 (+0.09%)
T   15.13 (-1.18%)
F   12.43 (+1.89%)
MU   68.88 (+1.44%)
CGC   0.84 (+9.09%)
GE   111.25 (-1.54%)
DIS   81.25 (-1.79%)
AMC   7.63 (-0.91%)
PFE   32.69 (-0.49%)
PYPL   57.88 (-1.26%)
NFLX   379.81 (-1.13%)
S&P 500   4,320.06 (-0.23%)
DOW   33,963.84 (-0.31%)
QQQ   357.91 (+0.01%)
AAPL   174.79 (+0.49%)
MSFT   317.01 (-0.79%)
META   299.08 (+1.13%)
GOOGL   130.25 (-0.15%)
AMZN   129.12 (-0.16%)
TSLA   244.88 (-4.23%)
NVDA   416.10 (+1.45%)
NIO   8.54 (+1.07%)
BABA   88.30 (+4.98%)
AMD   96.20 (+0.09%)
T   15.13 (-1.18%)
F   12.43 (+1.89%)
MU   68.88 (+1.44%)
CGC   0.84 (+9.09%)
GE   111.25 (-1.54%)
DIS   81.25 (-1.79%)
AMC   7.63 (-0.91%)
PFE   32.69 (-0.49%)
PYPL   57.88 (-1.26%)
NFLX   379.81 (-1.13%)
S&P 500   4,320.06 (-0.23%)
DOW   33,963.84 (-0.31%)
QQQ   357.91 (+0.01%)
AAPL   174.79 (+0.49%)
MSFT   317.01 (-0.79%)
META   299.08 (+1.13%)
GOOGL   130.25 (-0.15%)
AMZN   129.12 (-0.16%)
TSLA   244.88 (-4.23%)
NVDA   416.10 (+1.45%)
NIO   8.54 (+1.07%)
BABA   88.30 (+4.98%)
AMD   96.20 (+0.09%)
T   15.13 (-1.18%)
F   12.43 (+1.89%)
MU   68.88 (+1.44%)
CGC   0.84 (+9.09%)
GE   111.25 (-1.54%)
DIS   81.25 (-1.79%)
AMC   7.63 (-0.91%)
PFE   32.69 (-0.49%)
PYPL   57.88 (-1.26%)
NFLX   379.81 (-1.13%)
S&P 500   4,320.06 (-0.23%)
DOW   33,963.84 (-0.31%)
QQQ   357.91 (+0.01%)
AAPL   174.79 (+0.49%)
MSFT   317.01 (-0.79%)
META   299.08 (+1.13%)
GOOGL   130.25 (-0.15%)
AMZN   129.12 (-0.16%)
TSLA   244.88 (-4.23%)
NVDA   416.10 (+1.45%)
NIO   8.54 (+1.07%)
BABA   88.30 (+4.98%)
AMD   96.20 (+0.09%)
T   15.13 (-1.18%)
F   12.43 (+1.89%)
MU   68.88 (+1.44%)
CGC   0.84 (+9.09%)
GE   111.25 (-1.54%)
DIS   81.25 (-1.79%)
AMC   7.63 (-0.91%)
PFE   32.69 (-0.49%)
PYPL   57.88 (-1.26%)
NFLX   379.81 (-1.13%)
NASDAQ:ARQT

Arcutis Biotherapeutics (ARQT) Stock Forecast, Price & News

$5.38
-0.33 (-5.78%)
(As of 09/22/2023 ET)
Compare
Today's Range
$5.28
$5.84
50-Day Range
$5.71
$10.98
52-Week Range
$5.28
$20.64
Volume
947,958 shs
Average Volume
1.09 million shs
Market Capitalization
$331.68 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$43.43

Arcutis Biotherapeutics MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
707.2% Upside
$43.43 Price Target
Short Interest
Bearish
27.89% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.80mentions of Arcutis Biotherapeutics in the last 14 days
Based on 5 Articles This Week
Insider Trading
Selling Shares
$11,299 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($4.77) to ($3.92) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.10 out of 5 stars

Medical Sector

491st out of 968 stocks

Pharmaceutical Preparations Industry

214th out of 445 stocks


ARQT stock logo

About Arcutis Biotherapeutics (NASDAQ:ARQT) Stock

Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical foam formulation of roflumilast for the treatment of seborrheic dermatitis and scalp psoriasis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; ARQ-255, a topical formulation of ivarmacitinib designed to reach deeper into the skin in order to treat alopecia areata; and ARQ-234, a CD200R fusion protein for the treatment of moderate-to-severe atopic dermatitis. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.

ARQT Price History

ARQT Stock News Headlines

Bank Collapse Causes Gold Prices to Soar
Silicon Valley Bank was the second-largest bank in American history to fail, and investors have started piling into the safety and security of gold. But if you're not taking advantage of a little-known way to invest for around $5 today, you're missing out.
Goldman Sachs Sticks to Its Buy Rating for Arcutis Biotherapeutics (ARQT)
JonesTrading Reaffirms Their Buy Rating on Arcutis Biotherapeutics (ARQT)
Bank Collapse Causes Gold Prices to Soar
Silicon Valley Bank was the second-largest bank in American history to fail, and investors have started piling into the safety and security of gold. But if you're not taking advantage of a little-known way to invest for around $5 today, you're missing out.
Why Shares of Arcutis Biotherapeutics Fell This Week
Arcutis Appoints Interim Chief Financial Officer (CFO)
7 Analysts Have This to Say About Arcutis Biotherapeutics
JonesTrading Remains a Buy on Arcutis Biotherapeutics (ARQT)
See More Headlines
Receive ARQT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Arcutis Biotherapeutics and its competitors with MarketBeat's FREE daily newsletter.

ARQT Company Calendar

Last Earnings
8/08/2023
Today
9/22/2023
Next Earnings (Estimated)
11/14/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ARQT
Fax
N/A
Employees
268
Year Founded
2016

Price Target and Rating

Average Stock Price Forecast
$43.43
High Stock Price Forecast
$57.00
Low Stock Price Forecast
$22.00
Forecasted Upside/Downside
+707.2%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
6 Analysts

Profitability

Net Income
$-311,460,000.00
Net Margins
-2,837.94%
Pretax Margin
-2,837.94%

Debt

Sales & Book Value

Annual Sales
$3.69 million
Book Value
$3.44 per share

Miscellaneous

Free Float
48,892,000
Market Cap
$331.68 million
Optionable
Not Optionable
Beta
0.64

Social Links

7 Stocks to Buy And Hold Forever Cover

Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Key Executives

  • Mr. Todd Franklin Watanabe M.A.Mr. Todd Franklin Watanabe M.A. (Age 55)
    Pres, CEO & Director
    Comp: $1.01M
  • Dr. Bhaskar Chaudhuri Ph.D. (Age 68)
    Co-Founder & Independent Director
    Comp: $59.67k
  • Mr. Masaru Matsuda Esq. (Age 52)
    J.D., Sr. VP, Gen. Counsel & Corp. Sec.
    Comp: $626.22k
  • Dr. Patrick E. Burnett M.D. (Age 51)
    Ph.D., Sr. VP & Chief Medical Officer
    Comp: $689.95k
  • Mr. John W. Smither CPA (Age 70)
    Interim CFO & Principal Accounting Officer
  • Ms. Patricia A. TurneyMs. Patricia A. Turney (Age 56)
    Sr. VP of Operations
  • Mr. Rajvir Madan
    Chief Digital & Technology Officer
  • Mr. Eric McIntyre
    Head of Investor Relations
  • Ms. Courtney Barton (Age 40)
    VP and Chief Compliance Officer & Privacy Officer
  • Ms. Amanda Sheldon
    Head of Corp. Communications













ARQT Stock - Frequently Asked Questions

Should I buy or sell Arcutis Biotherapeutics stock right now?

6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Arcutis Biotherapeutics in the last twelve months. There are currently 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ARQT shares.
View ARQT analyst ratings
or view top-rated stocks.

What is Arcutis Biotherapeutics' stock price forecast for 2023?

6 Wall Street analysts have issued 12-month price objectives for Arcutis Biotherapeutics' stock. Their ARQT share price forecasts range from $22.00 to $57.00. On average, they predict the company's stock price to reach $43.43 in the next year. This suggests a possible upside of 707.2% from the stock's current price.
View analysts price targets for ARQT
or view top-rated stocks among Wall Street analysts.

How have ARQT shares performed in 2023?

Arcutis Biotherapeutics' stock was trading at $14.80 at the start of the year. Since then, ARQT shares have decreased by 63.6% and is now trading at $5.38.
View the best growth stocks for 2023 here
.

Are investors shorting Arcutis Biotherapeutics?

Arcutis Biotherapeutics saw a drop in short interest in August. As of August 31st, there was short interest totaling 12,480,000 shares, a drop of 19.2% from the August 15th total of 15,450,000 shares. Based on an average trading volume of 1,100,000 shares, the short-interest ratio is presently 11.3 days. Currently, 27.9% of the shares of the stock are short sold.
View Arcutis Biotherapeutics' Short Interest
.

When is Arcutis Biotherapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 14th 2023.
View our ARQT earnings forecast
.

How were Arcutis Biotherapeutics' earnings last quarter?

Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) announced its quarterly earnings data on Tuesday, August, 8th. The company reported ($1.16) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.22) by $0.06. The firm earned $5.19 million during the quarter, compared to analyst estimates of $4.87 million. Arcutis Biotherapeutics had a negative trailing twelve-month return on equity of 188.88% and a negative net margin of 2,837.94%.

What ETF holds Arcutis Biotherapeutics' stock ?

Virtus LifeSci Biotech Clinical Trials ETF holds 10,172 shares of ARQT stock, representing 0.89% of its portfolio.

What other stocks do shareholders of Arcutis Biotherapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Arcutis Biotherapeutics investors own include Black Diamond Therapeutics (BDTX), Pfizer (PFE), Akero Therapeutics (AKRO), Advanced Micro Devices (AMD), Applied Therapeutics (APLT), Aptinyx (APTX), BioNTech (BNTX), ServiceNow (NOW), Qualys (QLYS) and AbbVie (ABBV).

When did Arcutis Biotherapeutics IPO?

(ARQT) raised $125 million in an initial public offering (IPO) on Friday, January 31st 2020. The company issued 7,800,000 shares at a price of $15.00-$17.00 per share. Goldman Sachs, Cowen and Guggenheim Securities acted as the underwriters for the IPO and Cantor was co-manager.

What is Arcutis Biotherapeutics' stock symbol?

Arcutis Biotherapeutics trades on the NASDAQ under the ticker symbol "ARQT."

Who are Arcutis Biotherapeutics' major shareholders?

Arcutis Biotherapeutics' stock is owned by a number of institutional and retail investors. Top institutional investors include State Street Corp (8.48%), Rubric Capital Management LP (7.92%), Jennison Associates LLC (6.99%), BlackRock Inc. (6.86%), Polar Capital Holdings Plc (5.07%) and Marshall Wace LLP (3.76%). Insiders that own company stock include Bhaskar Chaudhuri, David W Osborne, Howard G Welgus, Howard G Welgus, John W Smither, Masaru Matsuda, Orbimed Advisors Llc, Patricia A Turney, Patrick Burnett, Scott L Burrows and Todd Franklin Watanabe.
View institutional ownership trends
.

How do I buy shares of Arcutis Biotherapeutics?

Shares of ARQT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Arcutis Biotherapeutics' stock price today?

One share of ARQT stock can currently be purchased for approximately $5.38.

How much money does Arcutis Biotherapeutics make?

Arcutis Biotherapeutics (NASDAQ:ARQT) has a market capitalization of $331.68 million and generates $3.69 million in revenue each year. The company earns $-311,460,000.00 in net income (profit) each year or ($5.54) on an earnings per share basis.

How many employees does Arcutis Biotherapeutics have?

The company employs 268 workers across the globe.

How can I contact Arcutis Biotherapeutics?

Arcutis Biotherapeutics' mailing address is 2945 TOWNSGATE ROAD SUITE 110, WESTLAKE VILLAGE CA, 91361. The official website for the company is www.arcutis.com. The company can be reached via phone at 805-418-5006 or via email at ir@arcutis.com.

This page (NASDAQ:ARQT) was last updated on 9/22/2023 by MarketBeat.com Staff

My Account -